In my very important and popular post from last year regarding topical finasteride, I discussed Polichem’s P-3074 product. P-3074 is “vehicled” in Hydroxypropyl-Chitosan (HPCH) per the latest announcements. Past references state that it uses hydroxypropyl-chitosan (HPCH) as the “film-forming agent”. I assume both those phrases/references essentially mean the same thing.
At this year’s just completed World Congress for Hair Research in Miami, one of the presentations pertained to this very product. The key quote from the abstract book:
“A pharmacokinetic phase I study, tested P-3074 b.i.d. [=twice per day] vs oral finasteride 1 mg o.d. [=once per day], revealing a finasteride systemic exposure 15 times lower in the topical formulation. A pharmacodynamic study compared P-3074 b.i.d. and o.d. vs oral finasteride 1 mg o.d. in DHT inhibition in scalp (vertex) and in serum. The results showed comparable serum/scalp DHT inhibitions across formulations, suggesting that the achievement of comparable levels of DHT inhibition vs the oral form could be attained by a lower dose of P-3074.”
My note: Their older report from the 7th World Congress for Hair Research from two years ago stated that the P-3074 product is composed of 0.25% finasteride. So the twice per day dose equals 0.50% per day. This is apparently lower than 1 mg/day oral finasteride per the implication of the last sentence in the above paragraph.
My note: They also state in the most recent abstract that at lower doses of 200 mcL, scalp DHT reduction remains unchanged. However, serum DHT reduction was much lower, potentially even further limiting systemic absorption. So 200mcL< 0.50% < 1mg.
Currently, P-3074 is in Phase III clinical trials in Europe.
I called my local compounding pharmacy a few months ago to inquire about them making topical finasteride for me. They told me that while they do make topical finasteride in gel form, they only get several such requests each year. Moreover, at around $100 per month, it is much more expensive than the cost of generic oral finasteride.
What I am really looking forward to is a topical dutasteride product with very low systemic absorption. The results from oral dutasteride are clearly superior to those from oral finasteride. Make sure to read the comments to my dutasteride (Avodart) user experiences post.
Unfortunately, oral dutasteride also results in significantly higher rates of side effects. We really need a topical version of dutasteride asap. Perhaps this will only happen after dutasteride is officially approved to treat hair loss.
Dr. Antonella Tosti is listed as a consultant to both Polichem and Kythera in the abstract I mentioned earlier.